Tempest Therapeutics Inc Asset Resilience Ratio
Tempest Therapeutics Inc asset resilience ratio. Tempest Therapeutics Inc (TPST) has an Asset Resilience Ratio of 1.38% as of March 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See TPST defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Tempest Therapeutics Inc (2012–2018)
Asset resilience ratio of Tempest Therapeutics Inc from 2012 to 2018. This chart shows how Tempest Therapeutics Inc's Asset Resilience Ratio has changed over time. Read Tempest Therapeutics Inc (TPST) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Tempest Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Tempest Therapeutics Inc total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $439.00K | 1.38% |
| Total Liquid Assets | $439.00K | 1.38% |
Asset Resilience Insights
- Limited Liquidity: Tempest Therapeutics Inc maintains only 1.38% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Tempest Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Tempest Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
Tempest Therapeutics Inc Asset Resilience Ratio by Year (2012–2018)
Tempest Therapeutics Inc asset resilience ratio by year from 2012 to 2018. The table below shows the annual Asset Resilience Ratio data for Tempest Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 5.22% | $4.38 Million | $84.07 Million | -52.28pp |
| 2016-12-31 | 57.50% | $70.46 Million | $122.54 Million | -2.70pp |
| 2015-12-31 | 60.19% | $83.44 Million | $138.61 Million | -21.88pp |
| 2014-12-31 | 82.07% | $53.82 Million | $65.57 Million | +26.65pp |
| 2013-12-31 | 55.42% | $26.35 Million | $47.55 Million | +4.79pp |
| 2012-12-31 | 50.63% | $16.61 Million | $32.81 Million | -- |
About Tempest Therapeutics Inc
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-14… Read more